Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Prednisolone Clear all
Completed Phase 2 Interventional

Study Evaluating the Efficacy of Administration of Cyclosporine (Low Dose and High Dose) and Prednisolone Acetate Compared to Its Components and Vehicle in Patients With Allergic Conjunctivitis

NCT01120132
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
CsA high dose, CsA low dose, PA, Placebo
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Jun 25, 2026, 5:26 PM EDT
Recruiting No phase listed Observational

A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement

NCT06430528
View directory record Official record
Conditions
Endogenous Cushing Syndrome, Adrenal Insufficiency, Hypercortisolism
Interventions
Osilodrostat
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Jun 25, 2026, 5:26 PM EDT
Recruiting Phase 2 Interventional

A Study to Prevent Infantile Spasms Relapse

NCT06819670
View directory record Official record
Conditions
Infantile Spasms, Infantile Epileptic Spasms Syndrome, West Syndrome
Interventions
Prednisolone, Famotidine, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
2 Months to 18 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 7, 2025 · Synced Jun 25, 2026, 5:26 PM EDT
Recruiting Phase 2 Interventional

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

NCT01624805
View directory record Official record
Conditions
Aplastic Anemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome
Interventions
Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, Methylprednisolone, Pegfilgrastim
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jun 25, 2026, 5:26 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Glucocorticoid Inflammation Paradox in Human Skeletal Muscle

NCT03529929
View directory record Official record
Conditions
Aging
Interventions
Methylprednisolone
Drug
Lead sponsor
Texas A&M University
Other
Eligibility
60 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Jun 25, 2026, 5:26 PM EDT
Recruiting Phase 3 Interventional

A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

NCT07365995
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
BNT324, Docetaxel, Prednisone/prednisolone
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older · Male only
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Rockville, Maryland • Nashville, Tennessee • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 25, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation

NCT00833495
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Prednisolone Acetate 0.12% (Pred Mild®), FOV1101-00, Prednisolone Acetate 1% (Pred Forte®), Placebo
Drug
Lead sponsor
Fovea Pharmaceuticals SA
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Jun 25, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients

NCT00494780
View directory record Official record
Conditions
Lymphoma, Follicular
Interventions
Ofatumumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, Prednisone or equivalent
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Jun 25, 2026, 5:26 PM EDT
Completed Phase 1 Interventional

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

NCT04666129
View directory record Official record
Conditions
Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer
Interventions
Relugolix, Abiraterone, Prednisone, Methylprednisolone, Apalutamide, Docetaxel
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
16
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Jun 25, 2026, 5:26 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Medrol Dosepak Taper for Delayed Post-op Recovery After TKA

NCT05113901
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
Methylprednisolone, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jun 25, 2026, 5:26 PM EDT
Terminated Not applicable Interventional

Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease

NCT00152620
View directory record Official record
Conditions
Inflammatory Bowel Disease (IBD)
Interventions
Dexamethasone, Methylprednisolone
Drug
Lead sponsor
University of Chicago
Other
Eligibility
6 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Jun 25, 2026, 5:26 PM EDT
Completed Phase 3 Interventional

Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201

NCT02887976
View directory record Official record
Conditions
Prostate Cancer
Interventions
SoluMatrix™ Abiraterone Acetate, Methylprednisolone
Drug
Lead sponsor
GU Research Network, LLC
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
3
States / cities
Wichita, Kansas • Lincoln, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Jun 25, 2026, 5:26 PM EDT
Not yet recruiting Phase 4 Interventional

Methylprednisolone Addition to Multimodal Pain Regimens After Anterior Cruciate Ligament Reconstruction

NCT07605923
View directory record Official record
Conditions
ACL Reconstruction
Interventions
Methyl Prednisolone (MP), Standard Post-Operative Pain Control, Surgeon's Standard ACL Postoperative Regimen
Drug · Combination Product
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jun 25, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation

NCT00066469
View directory record Official record
Conditions
Lymphoproliferative Disorder
Interventions
rituximab, cyclophosphamide, methylprednisolone, prednisone
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
66
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2019 · Synced Jun 25, 2026, 5:26 PM EDT
Recruiting Phase 4 Interventional

Once Weekly Infant Corticosteroid Trial for DMD

NCT05412394
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Prednisolone
Drug
Lead sponsor
Anne M. Connolly
Other
Eligibility
1 Month to 30 Months · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Cincinnati, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Jun 25, 2026, 5:26 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis

NCT01505088
View directory record Official record
Conditions
Anterior Uveitis
Interventions
40 mg/mL Dexamethasone phosphate ophthalmic solution, Prednisolone Acetate (1%) Eyedrops, 100 mM sodium citrate buffer solution, Placebo Eyedrops
Drug
Lead sponsor
Eyegate Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 85 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
39
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Jun 25, 2026, 5:26 PM EDT
Recruiting Phase 4 Interventional

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

NCT07101445
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Acetaminophen, Biospecimen Collection, Dexamethasone, Electronic Health Record Review, Famotidine, Loratadine, Methylprednisolone, Montelukast, Motixafortide, Pheresis, Questionnaire Administration, Recombinant Granulocyte Colony-Stimulating Factor
Drug · Procedure · Other + 1 more
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Jun 25, 2026, 5:26 PM EDT
Completed Phase 1 Interventional Results available

Safety and Efficacy of Topical Tacrolimus 0.05% in the Treatment of Ocular Graft-Versus-Host Disease

NCT01977781
View directory record Official record
Conditions
Ocular GVHD
Interventions
Tacrolimus, Methylprednisolone Sodium Succinate
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2017 · Synced Jun 25, 2026, 5:26 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis

NCT01201798
View directory record Official record
Conditions
Endogenous Anterior Uveitis
Interventions
Difluprednate 0.05% ophthalmic emulsion, Prednisolone acetate 1.0% ophthalmic suspension
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
2 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2012 · Synced Jun 25, 2026, 5:26 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Evaluation of Methylprednisolone or Ibuprofen on Efficacy of Nerve Blocks With Symptomatic Irreversible Pulpitis

NCT04157036
View directory record Official record
Conditions
Irreversible Pulpitis
Interventions
Ibuprofen, Methylprednisolone
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2022 · Synced Jun 25, 2026, 5:26 PM EDT
Completed Phase 4 Interventional

Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery

NCT04316936
View directory record Official record
Conditions
Cataract Surgery
Interventions
Omidria, Dextenza (dexamethasone ophthalmic insert) 0.4mg, Dexycu, 9% Intraocular Suspension, Prednisolone Acetate 1%
Drug
Lead sponsor
Silverstein Eye Centers
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Jun 25, 2026, 5:26 PM EDT
Terminated Not applicable Interventional Results available

Dexamethasone Versus Depo Medrol in Lumbar Epidurals

NCT01397552
View directory record Official record
Conditions
Lumbar Spine Disc Herniation, Lumbar Radiculitis, Lumbar Back Pain
Interventions
Dexamethasone, methylprednisolone acetate
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
21 Years to 89 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
East Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Jun 25, 2026, 5:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL

NCT01897571
View directory record Official record
Conditions
B-cell Lymphomas (Phase 1), Advanced Solid Tumors (Phase 1), Diffuse Large B-cell Lymphoma (Phase 2), Follicular Lymphoma (Phase 2), Transformed Follicular Lymphoma, Primary Mediastinal Large B-Cell Lymphoma
Interventions
Tazemetostat, Prednisolone
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
16 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • Duarte, California • Santa Barbara, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2024 · Synced Jun 25, 2026, 5:26 PM EDT
Completed Phase 4 Interventional Results available

Ideal Steroids for Asthma Treatment in the PICU

NCT03900624
View directory record Official record
Conditions
Asthma Childhood
Interventions
Dexamethasone
Drug
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
5 Years to 17 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Jun 25, 2026, 5:26 PM EDT